The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab

Abstract Background The combination of nivolumab + relatlimab is superior to nivolumab alone in the treatment of naive patients and has activity in PD-1 refractory melanoma. We had previously observed a reduced expression of LAG3 in melanoma tissue from patients with type 2 diabetes. Method To evalu...

Full description

Bibliographic Details
Main Authors: Domenico Mallardo, Rachel Woodford, Alexander M. Menzies, Lisa Zimmer, Andrew williamson, Egle Ramelyte, Florentia Dimitriou, Alexandre Wicky, Roslyn Wallace, Mario Mallardo, Alessio Cortellini, Alfredo Budillon, Victoria Atkinson, Shahneen Sandhu, Michielin Olivier, Reinhard Dummer, Paul Lorigan, Dirk Schadendorf, Georgina V. Long, Ester Simeone, Paolo A. Ascierto
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Journal of Translational Medicine
Subjects:
Diabetes
Nivolumab + relatlimab
Melanoma
LDH
Online Access:https://doi.org/10.1186/s12967-023-04607-4

Internet

https://doi.org/10.1186/s12967-023-04607-4

Similar Items